METHOD FOR PREDICTING THE STATUS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR HER2/NEU IN THE MAIN TUMOR NODE IN BREAST CANCER PATIENTS Russian patent published in 2021 - IPC G01T1/164 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, in particular to oncology, and can be used to predict the status of the epidermal growth factor receptor Her2/neu in primary tumors in breast cancer patients. At the diagnostic stage, after sampling the biopsy material, its morphological and immunohistochemical examination is carried out to determine the histological type of breast cancer and its molecular characteristics. Next, a radiopharmaceutical drug (RP) is administered based on ADAPT6 targeted molecules labeled with technetium-99m at a dose of 500 mcg. After 2 hours, a single-photon emission computed tomography (SPECT) of the chest organs is performed, in which the accumulation of RP in the breast tumor and the symmetrical area of the opposite breast selected as the background is evaluated. The tumor/background ratio is calculated 2 hours after the introduction of RP X1. The value of the regression equation Y is calculated using the formula Y=95.4-63.7 *X1, where 95.4 is the value of the regression coefficient of the free term; X1 is the tumor/background ratio 2 hours after the introduction of RP; X1=1 with a tumor/background ratio of ≤ 15.05; X1=2 with a tumor/background ratio > 15.05; 63.7 is the value of the regression coefficient of this feature. The probability P of evaluation of the status of the epidermal growth factor receptor Her2/neu in the primary tumor is determined by the formula: P=e^y /(1+e^y). At P≥50%, a high probability is predicted, and at P<50%, a low probability of Her2-positive status of the primary tumor node tissue.

EFFECT: method provides prediction of the status of the epidermal growth factor receptor Her2/neu in the primary tumor in breast cancer patients by assessing the accumulation of RP in the breast tumor and the symmetrical area of the opposite breast.

1 cl, 2 ex